Play all audios:
Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this
journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now
Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer
support AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * a Partner and chairman of the life sciences group at Wilson, Sonsini, Goodrich & Rosati, Palo Alto, CA J.Casey McGlynn * General
partner of Mayfield Fund, Menlo Park, CA Grant Heidrich Authors * J.Casey McGlynn View author publications You can also search for this author inPubMed Google Scholar * Grant Heidrich View
author publications You can also search for this author inPubMed Google Scholar RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE McGlynn, J., Heidrich, G.
Biotech financing remains a tough row to hoe. _Nat Biotechnol_ 13, 638–640 (1995). https://doi.org/10.1038/nbt0795-638 Download citation * Issue Date: 01 July 1995 * DOI:
https://doi.org/10.1038/nbt0795-638 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently
available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative